ORIGINAL RESEARCH article
Front. Oncol.
Sec. Skin Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1636411
Prevalence of skin cancers in kidney transplant recipients - one-center experience
Provisionally accepted- 1Medical University of Gdansk, Gdańsk, Poland
- 2Copernicus Hospital, Independent Public Healthcare, Dermalology and Venereology Clinic, Gdańsk, Gdańsk, Poland
- 3Private practice in dermatology and esthetic medicine, Gdynia, Gdynia, Poland
- 4Palliative Medicine Facility, Medical University of Gdańsk, Poland, Gdańsk, Poland
- 5Department of Internal Medicine and Pediatric Nursing, Faculty of Health Sciences, Medical University of Gdańsk, Poland, Gdańsk, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
INTRODUCTION: Non-melanoma skin cancers (NMSCs) are the most common neoplasms that occur in solid organ transplant recipients (SOTRs). Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) make up over 90% of skin cancers in SOTRs. Key risk factors include age at transplantation, skin type, immunosuppression, as well as sun exposure (ultraviolet radiation) and viral infections, contributing significantly to tumor development. This study aimed to estimate the incidence and risk of NMSCs in kidney transplant recipients (KTRs) in Poland and to provide new clinical data on patients developing skin cancers in this population. METHODS: This study included 105 KTRs, out of approximately 1,500, who were under the care of the Transplant Outpatient Clinic at the University Hospital in Gdansk between 1980 and 2022 and were diagnosed with NMSC. RESULTS: A total of 250 cutaneous malignancies were diagnosed in 105 KTRs. BCC (58.8%) and SCC (37.6%) were the most common histological types, and the SCC: BCC ratio was approximately 2:3. Other skin neoplasms, including malignant melanoma (2%) or hidradenocarcinoma, were significantly less frequent. The mean age of KTRs at the time of skin cancer diagnosis was 59.6 years, with a mean time from transplantation to cancer diagnosis of 103.2 months. Most skin cancers were diagnosed 5-10 years post-transplantation and were located on the .24%). The immunosuppressive therapy protocol did not significantly affect the risk of developing skin cancer. The only significant factor associated with an increased risk of skin cancer was patient age. One patient died due to metastatic SCC. CONCLUSION: NMSCs account for 90% of skin cancers in KTRs; they have a high recurrence rate and are most often found on the face of older patients towards the end of the first decade after transplantation.Our study confirms that the risk of further skin neoplasm is high and that SCC can be a cause of death. Early detection not only improves prognosis but also minimizes the extent of surgical interventions, which is particularly crucial for lesions in visible areas.
Keywords: Skin Neoplasms, Kidney Transplantation, Squamous cell, Basal cell, Carcinoma, Melanoma
Received: 27 May 2025; Accepted: 11 Sep 2025.
Copyright: © 2025 Kosko, Dębska-Ślizień, Imko-Walczuk, Piesiaków, Biedunkiewicz, Bułło-Piontecka, Bzoma, Chamienia, Gołębiewska, Konopa, Król, Liberek, Lichodziejewska-Niemierko, Lizakowski, Rutkowski, Tarasewicz, Wczysla and Heleniak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fabian Kosko, Medical University of Gdansk, Gdańsk, Poland
Zbigniew Heleniak, Medical University of Gdansk, Gdańsk, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.